CV Sciences (CVSI) Research & Development (2013 - 2026)
CV Sciences (CVSI) reported Research & Development of $18000.0 for Q1 2026, down 40.0% on a YoY basis from $30000.0 in Q1 2025, and little changed sequentially from $18000.0 in Q4 2025.
CV Sciences (CVSI) Research & Development (2013 - 2026) Analysis & Trends
CV Sciences (CVSI) has 14 years of Research & Development data on file, last reported at $18000.0 in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 40.0% year-over-year to $18000.0; the trailing twelve-month figure through Mar 2026 stood at $110000.0 (down 1.79% YoY), and the FY2025 full-year result was $122000.0, up 3.39% from the prior year.
- Research & Development was little changed at $18000.0 in Q1 2026, from $18000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $121000.0 in Q1 2022 to a low of $18000.0 in Q4 2025.
- A 5-year average of $42117.6 and a median of $36000.0 in 2023 frame the typical range for Research & Development.
- Across the five-year window, Research & Development plunged 89.27% in 2022 and soared 78.57% in 2025, its largest moves.
- Tracing CVSI's Research & Development over 5 years: stood at $40000.0 in 2022, then changed by 0.0% to $40000.0 in 2023, then sank by 37.5% to $25000.0 in 2024, then fell by 28.0% to $18000.0 in 2025, then changed by 0.0% to $18000.0 in 2026.
- Business Quant data shows CVSI's Research & Development at $18000.0 in Q1 2026, $18000.0 in Q4 2025, and $24000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 138.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 97.00 Mn |
| 10 | CV Sciences | 4.26 Mn | 3.95 Mn | 1.56 Mn | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 50,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 25,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Mar 31, 2024 | 36,000.00 |
| Dec 31, 2023 | 40,000.00 |
| Sep 30, 2023 | 40,000.00 |
| Jun 30, 2023 | 36,000.00 |
| Mar 31, 2023 | 35,000.00 |
| Dec 31, 2022 | 40,000.00 |
| Sep 30, 2022 | 44,000.00 |
| Jun 30, 2022 | 102,000.00 |
| Mar 31, 2022 | 121,000.00 |
| Dec 31, 2021 | 364,000.00 |
| Sep 30, 2021 | 410,000.00 |
| Jun 30, 2021 | 225,000.00 |